title: [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
abstract: Prevention of hypertension is one of the important strategies for decreasing future cardiovascular accidents. Antihypertensive drugs have never been used for the prevention of hypertension in clinical setting, however several animal studies have shown the renin-angiotensin inhibitors can prevent development of hypertension. TROPHY trial was designed to test whether candesartan, an angiotensin receptor blocker could prevent development of hypertension in subjects with high normal blood pressure level. From the TROPHY trial, candesartan did prevent development of hypertension by 66% at the end of its 2 year-administration. Candesartan also prevented development of hypertension by 42% even 2 years after session of its administration. TROPHY trial has shown that a use of angiotensin receptor blocker for the prevention of hypertension appears to be feasible in human.
authors.affiliation: Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus Schools of Medicine.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Ohya
authors.forename: Taku
authors.initials: T
authors.lastname: Inoue
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000517:prevention & control*; D051381:Rats; D012720:Severity of Illness Index; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan